Exuma Biotech

About:

EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.

Website: https://exumabio.com/

Twitter/X: BiotechExuma

Top Investors: BioAtla, Americo Financial Life and Annuity, F1 BioVentures, MSD Partners, SunTerra Capital

Description:

EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors. They develop new tools for the patient’s immune system to fight various solid tumor malignancies, such as renal cell carcinoma, soft tissue sarcoma, gastric cancer, and others. It was founded in 2015 and headquartered in Grand Cayman, Midland.

Total Funding Amount:

$107M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Grand Cayman, Midland, Cayman Islands

Founded Date:

2015-01-01

Contact Email:

info(AT)f1oncology.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2021-12-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai